Corpus Intelligence IC Memo — LAYTON HOSPITAL 2026-04-26 04:04 UTC
IC Memo — LAYTON HOSPITAL
Investment Committee Memorandum | UT | 37 beds | Grade B | EBITDA uplift $8.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

LAYTON HOSPITAL

CCN 460061 | DAVIS, UT | 37 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

LAYTON HOSPITAL is a 37-bed suburban community hospital in DAVIS, UT with $121.1M in net patient revenue and a 9.5% operating margin. The hospital serves a payer mix of 10.9% Medicare, 7.6% Medicaid, and 81.5% commercial.

Thesis: Turnaround. Our ML models identify $8.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 9.5% to 16.8% (+736bps).

Net Revenue HCRIS$121.1M
Current EBITDA COMPUTED$11.5M
Operating Margin COMPUTED9.5%
Occupancy HCRIS63.5%
Revenue / Bed COMPUTED$3.3M
Net-to-Gross HCRIS37.3%
Distress Probability ML42.8%

2. Market Context & Competitive Position

59
UT Hospitals
8.0%
State Median Margin
26
Comparable Hospitals

UT has 59 Medicare-certified hospitals with a median operating margin of 8.0%. The target's margin of 9.5% places it above the state median. Among 26 size-comparable peers (18-74 beds), the median margin is 3.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (18-74), prioritizing same-state peers. 26 hospitals in the comp set.

HospitalStateBedsRevenueMargin
LAYTON HOSPITAL (Target)UT37$121.1M9.5%
CEDAR CITY HOSPITALUT48$136.8M31.4%
LONE PEAK HOSPITALUT61$133.1M25.2%
ALTA VIEW HOSPITALUT57$130.9M-0.6%
GUNNISON VALLEY HOSPITALUT25$130.4M-6.4%
PARK CITY HOSPITALUT37$120.8M13.7%
UINTAH BASIN MEDICAL CENTERUT33$119.9M1.8%
MOUNTAIN WEST MEDICAL CENTERUT36$96.1M38.5%
THE ORTHOPEDIC SPECIALTY HOSPIUT40$88.7M12.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $8.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.5M+210bp18mo
Cost to Collect4.5%2.5%$2.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.5M+122bp9mo
Clean Claim Rate88.0%96.0%$78K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.5M
Cost to Collect
$2.4M
Denial Rate Reduction
$2.4M
A/R Days Reduction
$1.5M
Clean Claim Rate
$78K
Total EBITDA Uplift$8.9M
Current EBITDA$11.5M
+ RCM Uplift+$8.9M
Pro Forma EBITDA$20.4M
Current Margin9.5%
Pro Forma Margin16.8%
WC Released (1x)$4.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$17.6M$164.8M9.34x56.3%
Base (11x exit)10.0x11.0x$17.6M$187.0M10.60x60.3%
Bull Case9.0x11.0x$15.9M$222.2M13.99x69.5%
Bull (12x exit)9.0x12.0x$15.9M$247.1M15.55x73.1%
Bear Case11.0x10.0x$19.4M$114.5M5.90x42.6%
Bear (11x exit)11.0x11.0x$19.4M$132.3M6.81x46.8%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 26 hospitals with 18-74 beds
  • Same-state prioritization (n=27)
  • Comp margins: P25=-12.8% / P50=3.0% / P75=14.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.